Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

NCT01294670 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors
Relapsed/Refractory Sarcomas

Interventions

DRUG: Vorinostat and Etoposide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]